Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blaise

Showing results (221-230 of 284) with videos related to

Pageof 29
Sort By:
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Bone Marrow Transplantation|May 11, 2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantationM Mohty, J M Boiron, G Damaj, et al.
Leukemia|May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantationS Dietrich, H Finel, C Martinez, et al.
Bone Marrow Transplantation|September 16, 2014
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomasL Castagna, S Bramanti, S Furst, et al.
International Journal of Oncology|July 31, 1999
Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamideC Chabannon, J L Blache, I Sielleur, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Leukemia|August 22, 2003
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimenM Mohty, W Jacot, C Faucher, et al.
Pageof 29

Showing results (221-230 of 284) with videos related to

Sort By:
Pageof 29
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Bone Marrow Transplantation|May 11, 2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantationM Mohty, J M Boiron, G Damaj, et al.
Leukemia|May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantationS Dietrich, H Finel, C Martinez, et al.
Bone Marrow Transplantation|September 16, 2014
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomasL Castagna, S Bramanti, S Furst, et al.
International Journal of Oncology|July 31, 1999
Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamideC Chabannon, J L Blache, I Sielleur, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Leukemia|August 22, 2003
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimenM Mohty, W Jacot, C Faucher, et al.
Pageof 29